Introduction
miRNAs are an abundant class of endogenous small non-coding RNAs. Since the discovery of miRNAs, emerging studies have demonstrated that miRNAs could serve as oncogenes or tumor suppressors participating in initiation and progression of various cancers. 1 It is well documented that miRNAs can inhibit translation and/or induce degradation of target mRNAs, thereby negatively regulated gene expression.
cluster was found in tongue squamous cell carcinoma and prostate cancer (PCa). 7, 8 Several studies have shown that the expression levels of miR-221/222 cluster have close connections with occurrence, progression, and prognosis in several tumors. For instance, a receiver operating characteristic curve analysis conducted by Eissa et al revealed that the higher miR-221 expression, the worse 5-year relapse-free survival (RFS) in patients with BC (P=0.0124) 6 ; a recent study indicated that overall survival (OS) of higher miR-221 expression group was obviously lower than that of the lower miR-221 expression group (P<0.05). 9 Whereas, according to the log-rank test, including 125 triple-negative BC (TNBC) patients, Deng et al found that patients with high miR-221 expression have a better 5-year disease-free survival (DFS). 10 The aforementioned studies showed that miR-221/222 cluster could be potentially used in predicting the prognostic value of cancer. Meanwhile, the details of over-expressed miR-221/222 cluster's prognostic value in various cancer types are still controversial.
Meta-analysis is capable to obtain relatively accurate estimation by integrating all available evidence to explore authentic and comprehensive results. 11 The only meta-analysis regarding the prognostic value of miRNA-221/222 cluster in cancers was published in 2013 by Wang et al. 12 Thus, we carried out an updated meta-analysis with larger sample size, more cancer types, more ethnicities, and different analysis models to verify the previous conclusions and especially uncover some novel findings, which may contribute to the exploration of new promising biomarkers for assessing the therapeutic efficacy and prognostic value of different types of cancers.
Methods

search strategy
To search eligible studies, we explored literature resources consisting of PubMed, Cochrane Library, Embase, Chinese National Knowledge Infrastructure, and Chinese Biomedical Literature database, with the terms ("microRNA OR miRNA OR miR-221 OR miR-222 OR miR-221/222 cluster OR miR-221/222 family"), ("survival OR prognosis OR prognostic") and ("cancer OR tumor OR tumor OR neoplasm OR neoplasma OR neoplasia OR carcinoma OR Malignancy"). The deadline for current investigation was on January 30, 2018. Meanwhile, the language of publication was only limited to English and Chinese. To avoid omissions as much as possible, we checked through the references list in search of potentially relevant researches.
inclusion and exclusion
Available studies must obey the following criteria: 1) Clinical study about the correlation of miR-221/222 family with human cancer prognosis; 2) Study with relevant data of hazard ratios (HRs) with corresponding 95% CIs. Besides, studies met one of the criteria should be excluded as follows: 1) Studies with deficient data; 2) Duplicate studies (we select the study with relatively complete data); 3) Articles with other types, such as reviews and abstracts; and 4) Cell lines or animal models as research objects.
Data extraction
At the criteria of inclusion and exclusion, the corresponding data of qualified studies were extracted. If we noticed disagreements, a discussion would be conducted by PZ and MZ, or further reviewed by RH. The data, including first author, publication year, research country, test method, cancer type, miRNAs category, sample source, survival outcome, HR (95% CI), sample size, and the cutoff value were extracted to assess the tumor prognosis. Moreover, patient sources came from Asia, Africa, Europe, and North America. In situ hybridization (ISH) and reverse transcription-polymerase chain reaction (RT-PCR) were included in test methods; sample sources were divided into tissue, formalin-fixed and paraffin-embedded (FFPE), and blood; sample sizes included ≥100 and <100 groups; we just divided cancer types into 3 groups of hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), and others due to insufficient data; analyses methods included univariate and multivariate analyses. Patients' prognostic outcomes consisted of OS, DFS, RFS, and progression-free survival (PFS).
Data analysis
STATA (Version 12.0) and Review Manager (RevMan 5) softwares were utilized in this study. HR and corresponding 95% CI were extracted to evaluate the potential prognostic value of miR-221/222 cluster overexpression in human malignancy. Moreover, chi-square-based Q and I 2 tests have been applied in this study to assess the heterogeneity. (I 2 <25% means no heterogeneity, I 2 >50% means extreme heterogeneity). 13 Generally, we used fixed-effects model in studies with no or moderate heterogeneity. When I 2 >50% or P<0.01 for Q test occurred in studies, we always used random-effects model to avoid obvious heterogeneity.
14 Publications were individually deleted to assess the stability of the results and investigated the effect of each study on pooled HR. We evaluated the publication bias and attached the corresponding 
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Correlation between miRna-221/222 cluster and malignancy Begg's funnel plot. P<0.05 indicated a bias of study. 15 Correspondingly, we also carried out similar statistical analysis in different subgroups included country category, sample source, test method, sample size, miR-221/222 component, and cancer type.
Results
summary of included studies
Thirty-two studies consisted of 2,693 samples satisfied the eligible studies [4] [5] [6] [8] [9] [10] (Figure 1 ). 
Meta-analysis in Os
Twelve studies were included in univariate analysis to evaluate the prognostic value of overexpression of miR-221/222 cluster in human malignancy. Highly expressed miR-221/222 
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Correlation between miRna-221/222 cluster and malignancy cluster of tumors was connected with poor OS (HR =1.69, 95% CI: 1.18-2.44, P<0.01) (Figure 2A ). In addition, subanalyses results revealed that there were certain correlations (Table 2) . 15 studies were involved in multivariate analysis to conduct an evaluation regarding the prognostic value of miR-221/222 cluster. Meanwhile, tumor-associated miR-221/222 cluster overexpression also connected with poor OS (HR =2.10, 95% CI: 1.63-2.69, P<0.01) ( Figure 2B ). Similarly, several subgroups have an analogous result ( Table 2) .
Meta-analysis in DFs/PFs/RFs Figure S2 ).
sensitivity analysis
We removed each single study respectively to evaluate its specific effect on the mixed HRs, and sensitivity analysis indicated a relatively stable mixed result. Univariate and multivariate analyses of the pooled results (OS and DFS) were performed in Figure 4A , B and Figure S3A , B, but the result of PFS and RFS only in single-variate analysis was not shown.
Publication bias
According to Begg's funnel plot, there was no publication bias of OS (P=0.784>0.05) ( Figure 5A ), DFS (P=0.322>0.05), and PFS (P=0.624>0.05) among univariate analysis, and no publication bias of OS (P=0.324>0.05) ( Figure 5B), DFS (P=0.624>0.05), and RFS (P=0.497>0.05) among multivariate analysis. Similar to that, we also performed evaluations of subgroup of OS. There was no evidence for publication bias in any subgroup. However, the publication bias of PFS or RFS was not evaluated due to the fewer or no datasets for meta-analysis.
Discussion
Currently, exploring the clinically available cancer signatures is still the hotspot of researches due to the complexity of tumor. Dysregulations of distinct miRNA fingerprints often occur in specific types of human malignant tumors and obviously associated with cancer diagnosis, therapy, and even prognosis. 42, 43 Numerous studies have demonstrated that miR-221/222 cluster plays a significantly regulatory role in the prognosis of several types of tumors. For instance, miR-222 overexpression promoted HCC cell migratory through activating AKT phosphorylation assisted by the regulation of protein phosphatase 2A subunit B, contributing to both the development and poor prognosis of HCC. 16 Besides, it is reported that miR-221 negatively regulates poly ADP-Ribose 
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Correlation between miRna-221/222 cluster and malignancy polymerase 1 expression levels by 3′-untranslated region binding, thereby affecting TNBC patients' prognoses. 10 Meanwhile, overexpression of miRNA-221 enhanced cell proliferation via downregulating the target gene apoptotic protease activating factor-1 (APAF-1), while APAF-1 expression was associated with a poor prognosis. 44 It is reported that the upregulation of miR-221/222 cluster in GBM may be a key factor in the decrease of p27Kip1 expression levels and as such, will correlate with adverse prognosis. 45 Similarly, miRNA-222 could target HIPK2 to promote GC cell proliferation, invasion, and inhibited apoptosis, revealing a poor survival outcome for GC patients. 46 Moreover, the expression of miR-221 exhibited modulatory effect on BIM-Bax/ Bak axis, upregulated target gene BIM, induced by miR-221 knockdown, can promote cisplatin-eliciting apoptosis through inducing mitochondrial dysfunction, revealing a poor survival outcome for BC patients. 47 Hence, we proposed that activation or inhibition of multiple pathways might play Meta-analysis estimates, given named study is omitted Begg's funnel plot with pseudo 95% CI synergistic roles in the impact of miRNA-221/222 cluster expression on prognosis. However, the clinically prognostic value of dysregulated miR-221/222 expression often affected by small sample-size studies with insufficient data and thus inconsistent and unconvincing.
Meta-analysis is a useful tool, which can get a relatively precise result and provide convincing evidence through integrating and assessing inconsistent outcomes from different studies. We have explored the potential associations in overall population and the corresponding subgroups via combining univariate and multivariate analyses. Likewise, several subgroups have similar statistical results. However, no association of miR-221/222 family was detected with DFS/PFS/RFS.
Generally, we only explored the potential associations in corresponding subgroups of OS due to the sufficient data. When stratified by sample source, given the result in multivariate analysis, blood miR-221/222 expression was unlikely as a 
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Zhang et al promising marker on tumor prognosis. Meanwhile, the result was also not convincing in univariate analysis based on only one study. However, the miR-221/222 expression in FFPE or tissue might be associated with poor OS of carcinoma. When stratified by the sample size, we discovered that high expression of miR-221/222 cluster connected with unfavorable OS significantly in both groups with different sample sizes. When stratified by miRNA, the result indicated that the over expression of miR-221 and miR-222 both can predict poor OS apparently in multivariate analysis. However, we proposed overexpression miRNA-221/222 cluster could be viewed as a protection factor in PCa after integrating 4 studies on PCa 48 ( Figure S4 ). It is supposed that overexpression miRNA-221/222 cluster could repress PCa cell invasion 37 and decrease prostate-specific antigen expression mediated by androgen receptor, 49 which may participate in the protection process. Besides, lack of sufficient data indeed has a certain impact on the intriguing result. Future studies from multicenter comprising larger cohort size are needed to verify the current findings.
Actually, there were some limitations in our study that we should notice in the current meta-analysis. First, as for OS, part of the outcome failed to be analyzed separately due to the small sample size and no publication bias could be assessed in the current meta-analysis. In consideration of the limitations of qualified studies quantities, we did not process subgroup analysis for DFS/PFS/RFS. But the relative DFS/PFS/RFS data presented in this study may improve our understanding of cancer progression and relapse. Moreover, the design of studies, cutoff values, and measure methods being distinct in different studies, we could not consolidate those inconsistent objective elements, which were influential factors to the results. In addition, we did not compare the difference of ethnicities because of the limited number of different countries or races.
Conclusion
A significant correlation was explored in overall population and corresponding subgroups. Concretely, it presented that miR-221/222 family overexpression was significantly linked with poor OS, while no relationship was found between higher miR-221/222 family expression and DFS/PFS/RFS. Besides, sample sizes had no effect on our results, majority of subgroup analysis result was consistent with overall conclusion. Besides, miRNA-221/222 cluster from tissue or FFPE was more convincing in prediction of OS of tumor patients compared with blood-derived miRNA-221/222 cluster. Moreover, miRNA-221/222 cluster overexpression could be viewed as a protection factor in PCa to some extent. The elucidation of deregulated miR-221/222 cluster is expected to improve the understanding on tumor and promote the further development of biomarkers in cancer prognosis. 
A B
Meta-analysis estimates, given named study is omitted Lower CI limit 
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal
Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Dovepress
3381
Correlation between miRna-221/222 cluster and malignancy Figure S4 Forest plot of the association between high expression of miR-221/222 family in prostate cancer and DFs/RFs. Abbreviations: hR, hazard ratio; DFs, disease-free survival; RFs, relapse free survival; se, standard error. 
